Clinical outcomes and experience of patients with pure aortic regurgitation after transcatheter aortic valve replacement
10.3969/j.issn.1004-8812.2023.11.006
- VernacularTitle:经导管主动脉瓣置换术治疗单纯主动脉瓣反流的临床疗效分析及经验
- Author:
Long-Yan ZHANG
1
;
Zheng-Dong HUA
;
Dan SONG
;
Hui GUO
;
Cheng-Yi XU
;
Feng XIA
;
Bo LIU
;
Wei-Qin HUANG
;
Jing LI
;
Zhi-Lin ZHONG
;
Yue ZHANG
;
Ying WANG
;
Xi SU
Author Information
1. 430056 湖北武汉,武汉亚心总医院心血管内科
- Keywords:
Transcatheter aortic valve replacement;
Pure aortic regurgitation;
Early clinical effect;
Valve stability
- From:
Chinese Journal of Interventional Cardiology
2023;31(11):842-848
- CountryChina
- Language:Chinese
-
Abstract:
Objective The aim of this study is to investigate the efficacy of using transcatheter aortic valve replacement(TAVR)with self-expanding valve(SEV)to treat patients with pure aortic regurgitation(PAR)and to understand the preliminary experience of such procedure.Methods A total of 20 PAR patients who underwent TAVR using the TaurusElite system at Wuhan Asia Heart Hospital and Wuhan Asia Heart Disease Hospital from April 2022 to May 2023 were included in the study.Patient baseline data,echocardiographic data,follow-up data during hospitalization and 30 days after the procedures were collected and analyzed.Results The mean age of the patients was(73.5±5.5)years,and the mean STS score was(8.7±3.6)％.16(16/20)cases had severe PAR before the procedure.After TAVR treatment,the success rate of the procedure was 20/20,with only 1 case of valve-in-valve(ⅥⅤ).The 30-day follow-up results showed that none of the 20 patients experienced death,disabling stroke,myocardial infarction,and conversion to surgery.The degree of residual PAR after the procedure was none or mild in all patients.The interventional outcome was ideal.Conclusions The preliminary experience shows that,with strict patient selection and standardized procedural steps,using TAVR with SEV to treat patients with PAR could have high feasibility and ideal early clinical outcomes and can potentially be popularized.Such experience will be further validated in future clinical trials.
